Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 13/20 | 0.80 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.71 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376516 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL18784962 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL104629 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| SCHEMBL376515 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL10044131 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL104630 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL105273 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL15810768 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL315351 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL21311175 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250180555-A1 | SINGLE-MOLECULE ANALYSIS OF NUCLEIC ACID BINDING PROTEINS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-06-05 | — | — | US | claimed |
| EP-1594987-B1 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | GENEFORM TECHNOLOGIES LTD (GB) | 2009-05-27 | — | — | EP | claimed |
| EP-4724107-A2 | OPHTHALMIC FILMS | Fount Bio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4687923-A1 | T CELLS FOR USE IN TREATING RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA | Takeda Pharmaceutical Company Limited (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260034176-A1 | T CELLS FOR USE IN TREATING RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA | TAKEDA PHARMACEUTICALS CO (JP) | 2026-02-05 | — | — | US | disclosed |
| US-20260028621-A1 | METHOD FOR ENCODING DIGITAL DATA ON NUCLEIC ACIDS USING BIOLOGICAL PROCESSES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2026-01-29 | — | — | US | disclosed |
| US-20260014183-A1 | LOW-INTENSITY TREATMENT OF HEMATOLOGICAL DISORDERS | JAZZ PHARMACEUTICALS THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-3076946-B1 | COMPOSITIONS COMPRISING ANTIOXIDANT, FLUID DISPENSERS, AND METHODS INVOLVING THE SAME | ALZET LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12516302-B2 | DNA polymerase theta mutants, methods of producing these mutants, and their uses | INSTITUT PASTEUR (FR) | 2026-01-06 | — | — | US | disclosed |
| US-20250360157-A1 | CYTOTOXIC FLUOROPYRIMIDINE POLYMERS AND METHODS OF USE THEREOF | Wake Forest Univesity Health Sciences (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4630567-A2 | CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AND USES THEREOF | Research Institute at Nationwide Children's Hospital (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-3955887-A1 | DELIVERY AND RETENTION OF ACTIVE AGENTS WITHIN THE SKIN | Fount Bio, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20210340612-A1 | PROCESS FOR COGNATE NUCLEOTIDE DETECTION IN A NUCLEIC ACID SEQUENCING WORKFLOW | Omniome, Inc. (US) | 2021-11-04 | — | — | US | disclosed |
| US-10975427-B2 | Process for cognate nucleotide detection in a nucleic acid sequencing workflow | Omniome, Inc. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20180208983-A1 | PROCESS FOR COGNATE NUCLEOTIDE DETECTION IN A NUCLEIC ACID SEQUENCING WORKFLOW | Omniome, Inc. (US) | 2018-07-26 | — | — | US | disclosed |
| US-8399196-B2 | Nucleic acid sequencing methods, kits and reagents | GENEFORM TECHNOLOGIES LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20090143236-A1 | Method of detecting cancer cell acquiring drug-resistance | BML, INC. (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1594987-B1 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | GENEFORM TECHNOLOGIES LTD (GB) | 2009-05-27 | — | — | EP | disclosed |
| US-20070148645-A1 | Nucleic acid sequencing methods, kits and reagents | GENEFORM TECHNOLOGIES LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
| EP-1715041-A1 | METHOD OF DETECTING CANCER CELL ACQUIRING DRUG-RESISTANCE | BML, Inc. (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208983-A1 | PROCESS FOR COGNATE NUCLEOTIDE DETECTION IN A NUCLEIC ACID SEQUENCING WORKFLOW | RNGTT, POLRMT, POLM | P2RY2 1576/4885P2RY6 706/4885P2RY4 625/4885 |
| US-20260014183-A1 | LOW-INTENSITY TREATMENT OF HEMATOLOGICAL DISORDERS | MCL1, BCL9, BCL9L | P2RY2 368/4885P2RY6 1074/4885P2RY4 792/4885 |
| US-20070148645-A1 | Nucleic acid sequencing methods, kits and reagents | UNG, DNTT, RNGTT | P2RY2 3016/4885P2RY6 1915/4885P2RY4 2195/4885 |
| US-20260028621-A1 | METHOD FOR ENCODING DIGITAL DATA ON NUCLEIC ACIDS USING BIOLOGICAL PROCESSES | NSUN2, RNMT, RNGTT | P2RY2 496/4885P2RY6 354/4885P2RY4 575/4885 |
| US-10975427-B2 | Process for cognate nucleotide detection in a nucleic acid sequencing workflow | RNGTT, POLRMT, POLM | P2RY2 1576/4885P2RY6 706/4885P2RY4 625/4885 |
| US-20250360157-A1 | CYTOTOXIC FLUOROPYRIMIDINE POLYMERS AND METHODS OF USE THEREOF | DPYD, DUT, UNG | P2RY2 3816/4885P2RY6 2766/4885P2RY4 3497/4885 |
| US-20210340612-A1 | PROCESS FOR COGNATE NUCLEOTIDE DETECTION IN A NUCLEIC ACID SEQUENCING WORKFLOW | RNGTT, POLRMT, POLM | P2RY2 1576/4885P2RY6 706/4885P2RY4 625/4885 |
| US-20260034176-A1 | T CELLS FOR USE IN TREATING RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA | CTNND1, PRKCD, MCL1 | P2RY2 595/4885P2RY6 995/4885P2RY4 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.